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Introduction and objectives. Prognosis and in-hospital 
management of patients with acute coronary syndrome 
(ACS) and a history of coronary artery bypass graft (CABG) 
surgery are still debated. The objective of this study was 
to characterize ACS patients with a CABG and to compare 
their in-hospital and postdischarge outcomes with those 
of patients without a CABG.
Methods. This ongoing prospective observational 
study included 1,495 consecutive patients admitted for 
ACS to a coronary care unit and followed up for a mean of 
19 months. There were two groups: group A (n=73), with 
CABGs; and group B (n=1,223), without CABGs.
Results. Group A patients were more often male (86.3% 
versus 69.1%; P=.002), and more frequently had a history 
of diabetes, myocardial infarction and heart failure. Group 
B patients more frequently had ST-elevation myocardial 
infarction, and had a higher median ejection fraction (53% 
[interquartile range, 47%-60%] vs. 50% [42%-55%]; 
P<.01) and peak troponin-I concentration. There was no 
difference in the use of invasive techniques. Regarding 
medication, Group B patients were more likely to receive 
dual antiplatelet therapy at discharge. No significant 
difference was observed in in-hospital mortality (9.5% 
versus 5.9%; P=.2) or mortality at 1 month, 6 months 
or 1 year (9.8% versus 9.1%; log-rank test, P=.87) and 
the cumulative major adverse cardiac event rate was 
equally low in both groups. The presence of a CABG was 
associated with more readmissions for unstable angina 
(11.3% vs. 3.1%; P<.01).
Conclusions. In our ACS patients, the presence of a 
CABG had no significant influence on short- or medium-
term outcomes, such as all-cause mortality and adverse 
cardiac events.
Key words: Coronary artery bypass graft. Acute coronary 
syndrome. Prognosis.
¿Podemos mejorar la evolución de los 
pacientes con antecedentes de cirugía de 
bypass coronario ingresados por un síndrome 
coronario agudo?
Introducción y objetivos. El pronóstico y el tratamien-
to en el hospital de los pacientes con síndrome coronario 
agudo (SCA) y antecedentes de cirugía de bypass coro-
nario (CABG) es motivo de controversia. El objetivo de 
este estudio es caracterizar a los pacientes con SCA que 
tienen antecedentes de CABG y comparar su evolución 
intrahospitalaria y extrahospitalaria con la de los pacien-
tes sin antecedentes de CABG.
Métodos. Estudio prospectivo observacional continuo 
de 1.495 ingresos consecutivos por SCA en una misma 
unidad coronaria, con un seguimiento medio de 19 meses. 
Se dividió a los pacientes en dos grupos: grupo A (n = 73) 
con CABG previa y grupo B (n = 1.223) sin CABG previa. 
Resultados. Los pacientes del grupo A eran con mayor 
frecuencia varones (el 86,3 frente al 69,1%; p = 0,002), 
tenían antecedentes más frecuentes de diabetes melli-
tus, infarto de miocardio previo e insuficiencia cardiaca. 
Los pacientes del grupo B tenían más infartos agudos de 
miocardio con elevación del ST, una fracción de eyec-
ción más alta (53% [47%-60%] frente a 50% [42%-55%]; 
p < 0,01) y valores superiores de concentración máxima 
de troponina I. No se observaron diferencias en cuanto al 
uso de una estrategia invasiva. Por lo que respecta a la 
medicación, los pacientes del grupo B tenían una mayor 
probabilidad de recibir doble tratamiento antiagregante al 
alta. No se observaron diferencias significativas en cuanto 
a la mortalidad hospitalaria (el 9,5 frente al 5,9%; p = 0,2) 
ni en la mortalidad a 1 mes, 6 meses o 1 año (el 9,8 frente 
al 9,1%; log-rank test, p = 0,87), y la ausencia acumula-
tiva de eventos adversos cardiovasculares mayores fue 
también similar en ambos grupos. Los antecedentes de 
CABG se asociaron a una mayor frecuencia de reingresos 
por angina inestable (el 11,3 frente al 3,1%; p < 0,01).
Conclusiones. En nuestra población con SCA, el an-
tecedente de CABG no influyó de manera significativa en 
la evolución a corto y medio plazo en cuanto a la morta-
lidad por cualquier causa o eventos adversos cardiovas-
culares mayores. 
Palabras clave: Bypass coronario previo. Síndrome co-
ronario agudo. Pronósticos.
See editorial on pageS  516-7
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Acute Coronary Events (GRACE),12 or PURSUIT13 
scores. In contrast, several small series suggest a 
more favorable outcome for this group of patients, 
for both MI14 and unstable angina (UA).15
Although no randomized studies have been 
designed to evaluate the benefits of an invasive 
versus conservative strategy in patients who have 
already undergone CABG, recent guidelines 
recommend a low threshold for angiography with 
a preferable intervention in native circulation, 
and medical treatment similar to that used in the 
overall population (class I recommendation, level of 
evidence C).16
Due to the lack of data for this important subgroup 
of ACS patients when compared to others, we 
decided to proceed to an analysis of the in-hospital 
and medium-term prognosis of an unselected ACS 
population with previous CABG from a single 
center. 
METHODS
A continuous, observational, prospective study 
of 1495 consecutive admissions for ACS between 
May 2004 and December 2006 was conducted in a 
single coronary care unit. We excluded 130 patients 
because they were readmissions, and an additional 
33 due to incomplete data. The final population 
consisted of 1296 patients.
ST-elevation AMI (STEMI) was defined as 
ischemic chest pain associated with new onset ST 
elevation greater than 1 mm in the ECG in at least 2 
contiguous leads. 
Non-ST AMI (NSTEMI) was synonymous with 
ischemic chest pain lasting more than 5 minutes, 
and positive cardiac biomarkers (troponin I) with or 
without ECG ischemic changes (eg, ST depression 
or T-wave inversion). 
UA was defined as new onset angina (at least 
class III Canadian Cardiovascular Society [CCS]), 
progressive angina, or angina at rest, with or without 
ECG ischemic changes. 
All patients gave written informed consent 
for participation, and the local ethics committee 
approved the study.
We analyzed standard records during admission, 
including the following data: demographic, clinical, 
electrical, echocardiography, laboratory, medical 
therapy, catheterization, in-hospital course, and 
discharge medication. 
Median clinical follow-up after hospital discharge 
was 19 months. The information was collected by 
phone, at the outpatient clinic, or from hospital 
records in the event of a local repeated hospital 
admission. The primary endpoint was all-cause 
mortality and the combined result of cardiovascular 
death, nonfatal infarction, readmission for UA, 
INTRODUCTION
Since its introduction in clinical practice 40 years 
ago, coronary artery bypass grafting (CABG) is a 
well-recognized treatment for stable coronary artery 
disease, with a major impact on survival.1
Long-term follow-up studies report 67% survival 
free of myocardial infarction (MI) 20 years after 
CABG.2 More recent data indicated an incidence of 
MI of 2% to 3% per year over the first 5 years, with 
a 5-year cumulative incidence of non-fatal MI of 
15%,3 and a recurrent infarction in as many as 36% 
of patients at 10 years.4 Furthermore, CABG has a 
positive influence on long-term quality of life and 
functional capacity.5
On the other hand, observational studies on 
acute coronary syndromes (ACS) noted an overall 
prevalence of 20% for patients with a history of 
CABG.6,7
In these patients, there are 2 potential explanations, 
not mutually exclusive, for a new major coronary 
event, namely, progression of atherosclerotic 
disease in native arteries or the development of 
vascular disease in the grafts. Previous authors of an 
angiography study reported 8% venous graft failure 
at 1 year, 38% at 5 years, and 75% at 10 years after 
surgery,8 and progression of the atherosclerotic 
process in up to 51% 15 years after CABG.9 
The prognosis of this subset of patients, 
nevertheless, remains doubtful. The Thrombolysis 
in Myocardial Infarction (TIMI) III ACS subset 
registry found a similar result during the hospital 
stay and at 6 months; however, by 1 year the 
subgroup of patients with a history of CABG had 
a poorer prognosis (incidence of combined events, 
39.3% vs 30.2%; P=.002).10 Despite the poorer 
outcome, previous CABG was not an independent 
predictor of death in TIMI,11 Global Registry of 
ABBREVIATIONS
ACS: acute coronary syndrome
BMS: bare-metal stent
CABG: coronary artery bypass graft
DES: drug-eluting stent
MI: myocardial infarction
NSTEMI: non-ST-elevation myocardial 
infarction
STEMI: ST-elevation myocardial infarction
UA: unstable angina
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All statistical tests were 2-tailed, and a P less than 
.05 was considered significant. All analyses were 
performed using SPSS 15 (Statistical Package for 
Social Sciences, SPSS Inc, Chicago, Illinois, United 
States).
RESULTS
The population was divided into 2 groups based 
on a history of CABG. Group A included 73 patients 
with previous CABG and group B, 1223 with no 
previous history of myocardial revascularization 
surgery.
Baseline Characteristics
The study cohort included 908 men and 388 
women with a mean age of 67.0 (12.6) years; 5.6% 
had a history of CABG.
The baseline demographic and clinical characteristics 
of both groups are shown in Tables 1 and 2. 
Patients with a history of CABG were more likely 
to be male, more often admitted for NSTEMI and 
UA, and more likely to have a history of diabetes, 
previous infarction, and PCI. 
and percutaneous coronary intervention as major 
adverse cardiac events (MACE). We also recorded 
MI, readmission for heart failure, and stroke. 
Statistical Analysis
Continuous data are presented as the median 
[interquartile range] and compared using the Mann-
Whitney test, or as the mean [SD], and compared 
using the Student t test. Categorical variables 
are reported as frequencies and percentages, and 
the c2 test or the exact Fisher test was used when 
appropriate. 
The cumulative survival curves were constructed 
using the Kaplan-Meier methods, and the 
groups were compared by the log-rank test. The 
observational period started at hospital discharge 
and ended 1 year after the ACS.
A Cox regression analysis was performed for the 
clinical endpoint of UA 1 year after the ACS. The 
variables included in the model were significant at P 
less than .05 in the univariate analysis and included 
a history of CABG, diabetes, age over 75 years, 
STEMI, left ventricular ejection fraction (LVEF) 
lower than 40%, and invasive strategy.
TABLE 1. Baseline Characteristics 
 A (Previous CABG) B (No Previous CABG) P
Number of patients 73 1223 
 Female gender 10/73 (13.7) 378/1223 (30.9) .001
 Mean, age (SD), y 69.2 (9.4) 66.9 (12.7) .13
Admission diagnosis   
 STEMI 6/69 (8.7) 431/1183 (36.4) <.001
 NSTEMI 41/69 (59.4) 518/1183 (43.8) .01
 UA 20/69 (29.0) 199/1183 (1.8) .01
 Undetermined pattern 2/69 (2.9) 35/1183 (3.0) .98
Risk factors for cardiovascular disease   
 Diabetes 29/71 (40.8) 346/1208 (28.6) .028
 Dyslipidemia 53/68 (77.9) 803/1123 (71.5) .25
 Hypertension 55/70 (78.6) 808/1135 (71.2) .18
 Smoker 6/73 (8.2) 234/1223 (19.1) .02
Cardiovascular history   
 History of infarction 32/55 (58.2) 172/1095 (15.7) <.001
 History of PCI 14/65 (21.5) 109/1184 (9.2) .001
 History of heart failure 2/23 (8.7) 11/493 (2.2) .053
Previous therapy   
 ASA 45/57 (78.9) 274/729 (37.6) <.001
 Other antiplatelets 9/57 (15.8) 108/729 (14.8) .84
 Beta blockers 24/57 (42.1) 163/729 (22.4) .001
 ACE inhibitors 28/57 (49.1) 302/729 (41.4) .26
 Statins 31/57 (54.4) 217/729 (29.8) <.001
 Diuretics 15/57 (26.3) 172/729 (23.6) .64
 Nitrates 20/57 (35.1) 142/729 (19.5) .005
ACE inhibitors indicates angiotensin converting enzyme inhibitors; ASA, acetylsalicylic acid; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; UA, unstable angina.
Values are shown as n/No. (%) or mean (SD).
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were the most common option (Table 3). All patients 
were operated with classic on-pump surgery.
In-Hospital Management
An invasive strategy was used in 38 (52.1%) 
CABG patients, compared to 732 (59.9%) non-
CABG patients. Despite these absolute differences, 
both groups had a similar probability of receiving 
invasive treatment. There were no significant 
differences regarding medical treatment during the 
first 24 hours (Table 4).
Regarding catheterization laboratory data after 
admission for ACS, patients with a history of 
CABG had, as expected, more extensive coronary 
involvement (Table 5).
In 50% of patients with previous CABG, we 
concluded that graft lesions were contributing to 
the ACS. PCI was performed in 73.2% (460/628) of 
patients with no history of CABG, compared to 47.1% 
Left bundle-branch block and a higher TIMI 
risk score were more frequently associated with 
a history of CABG, as was a lower LVEF (50.0% 
[42.0%-55.0%] vs 53.0% [46.75%-60%], P<.001). In 
contrast, a higher peak troponin I was present in 
group B patients.
Previous History
The present ACS that prompted inclusion in the 
study occurred a median of 9 (4-12.5) years after 
CABG. Multivessel coronary artery disease was 
the most frequent coronary anatomic abnormality 
before surgery, and 13% and 37% of patients had 
lesions in the left main artery and proximal left 
anterior descending artery, respectively.
Arterial bypasses (only mammary internal bypass 
were performed) were more common than venous 
bypasses, and 83.3% of patients were treated by both 
types. Triple (38.9%) and double (37.0%) bypasses 
TABLE 2. Hemodynamic, Electrical, and Laboratory Data
 A (Previous CABG) B (No Previous CABG) P
Hemodynamic data on admission
 Heart rate, bpm 70 [63-80] 72 [61-83] .028
 Systolic blood pressure, mmHg 136 [120-150] 137 [120-160] .42
 Diastolic blood pressure, mmHg 70 [63-80] 72 [61-83] .92
 Killip-Kimball
  Class I 58/66 (87.9) 990/1176 (84.2) .42
  Class II 6/66 (9.1) 151/1176 (12.8) .37
  Class III 1/66 (1.5) 18/1176 (1.5) .99
  Class IV 0/66 (0) 17/1176 (1.4) .96
 TIMI risk score
  ≤2 8/73 (11.0) 589/1233 (47.8) <.001
  3-4 33/73 (45.2) 527/1233 (42.7) .67
  ≥5 32/73 (43.8) 117/1233 (9.5) <.001
 LVEF 50 [42-55] 53 [46.75-60] .006
 Body mass index, kg/m2 26.5 [24.8-28.3] 27.2 [24.5-29.4] .44
Electrical data on admission
 Sinus rhythm 61/71 (85.9) 1061/1223 (87.8) .63
 AF 3/71 (4.2) 104/1028 (8.6) .20
 T-wave inversion 12/71 (16.9) 207/1208 (17.1) .96
 ST depression 12/71 (16.9) 121/1028 (10.0) .065
 LBBB 9/71 (12.7) 51/1208 (4.2) .001
Laboratory data
 Peak troponin I, U/L 6.9 [1.8-21.3] 15.6 [3.8-53.8] .001
 Peak CK-MB, U/L 20.5 [4.0-59.5] 54.3 [12.0-173.5] .001
 LDL-C, mg/dL 117 [90-144] 125 [105-150] .36
 Glomerular filtration rate, mL/min 66 [43-77] 70 [50-91.25] .078
 Blood glucose at admission, mg/dL 140 [106-182] 129 [108-175] .73
 Hemoglobin at admission, g/dL 13.6 [12.5-14.7] 13.9 [12.6-15.0] .37
 Minimum hemoglobin, g/dL 12.5 [10.7-13.3] 12.3 [10.9-13.3] .86
AF indicates atrial fibrillation; CABG, coronary artery bypass graft; CK-MB, creatine kinase MB; LBBB, left bundle branch block; LDL-C, low-density lipoprotein cholesterol; 
LVEF, left ventricular ejection fraction; TIMI, Thrombolysis in Myocardial Infarction.
Values are shown as n (%) or mean [interquartile range].
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(16/34) of those who did (P=.001). Group B patients 
were also more likely to be fully revascularized 
and treated with a stent. Nevertheless, the odds for 
receiving a drug-eluting stent (DES) were similar in 
both groups. No patient in group A underwent a 
second surgical revascularization procedure.
We analyzed 55 venous grafts in the 38 patients 
admitted for an invasive procedure. There were 
54.2% total occlusions, and most lesions were in 
the ostial and proximal segments of the grafts. In 
the case of arterial bypass grafts, a total of 30 grafts 
were analyzed. Significant atherosclerotic lesions 
were identified in only 6; half of these also had total 
occlusions.
PCI was performed in 7 patients in the venous 
grafts (Table 6). 
Despite the lower rate of dual antiplatelet therapy, 
at discharge there were no other differences between 
groups with regard to aspirin, statin, ACE inhibitor, 
or beta blocker therapy.
TABLE 3. Previous Surgical History
CABG Patients
Time after surgery, y 9 [4-12.5]
1-vessel coronary disease before CABG 6/54 (11.1)
2-vessel coronary disease before CABG 12/54 (22.2)
3-vessel coronary disease before CABG 35/54 (65.0)
Left main artery disease before CABG 7/54 (13.0)
Proximal LAD disease before CABG 20/54 (37.0)
Arterial bypass 51/54 (94.4)
Saphenous bypass 48/54 (88.9)
Arterial and venous bypass 45/54 (83.3)
1 bypass 8/54 (14.8)
2 bypasses 20/54 (37.0)
3 bypasses 21/54 (38.9)
4 bypasses 5/54 (9.3)
On-pump time, min 65 [45-74]
LVEF at time of CABG, % 60 [50-67]
ACABG indicates coronary artery bypass graft; LAD, left anterior descending artery; 
LVEF, left ventricular ejection fraction.
Data are expressed as n (%) or median [interquartile range].
TABLE 4. In-Hospital Management
 First 24 Hours Medication at Discharge
 Previous CABG (n=73) No Previous CABG (n=1223) P Previous CABG No Previous CABG P
GP IIb/IIIa inhibitors 39 (53.4) 589 (48.2) .38 
Diuretics 28 (38.4) 361 (29.5) .11 
ASA 70 (95.9) 1171 (95.7) .95 64 (87.7) 1070 (87.5) .96
Clopidogrel 48 (65.8) 828 (67.7) .73 27 (37) 602 (49.2) .042
Beta-blockers 58 (79.5) 973 (79.6) .98 58 (79.5) 934 (76.4) .55
ACE inhibitors 66 (90.4) 1091 (89.2) .75 62 (84.9) 1050 (85.9) .83
Statins 72 (98.6) 1192 (97.5) .53 66 (90.4) 1162 (95.0) .087
Calcium channel blockers 9 (12.3) 82 (6.7) .07 
Nitrates 35 (47.9) 465 (38) .09 
ACE inhibitors indicates angiotensin-converting enzyme inhibitors; ASA, acetylsalicylic acid; CABG, coronary artery bypass graft; GP, glycoprotein.
Data are expressed as n (%) or median [interquartile range].
TABLE 5. Catheterization Laboratory Data
 A (Previous CABG) B (No previous CABG) OR (95% CI) P
Primary PCI 5/5 (100) 305/329 (92.7)  .53
Invasive strategy 38/73 (52.1) 732/1233 (59.9) 0.84 (0.65-1.1) .19
1-vessel coronary disease 8/38 (21.1) 311/732 (42.5) 0.36 (0.16-0.8) .009
2-vessel coronary disease 6/38 (15.8) 169/732 (23.1) 0.63 (0.26-1.52) .29
3-vessel coronary disease 23/38 (61) 141/732 (19.3) 4.19 (2.16-8.13) <.001
Left main artery 4/38 (10.5) 28/732 (3.8) 2.96 (0.98-8.91) .067
Arterial bypass 6/38 (15.8) 0  
Saphenous bypass 13/38 (34.2) 0  
PCI 16/34 (47.1) 460/628 (73.2) 0.33 (0.16-0.65) .001
Fully revascularized 7/34 (20.6) 312/628 (49.7) 0.26 (0.11-0.61) .001
Partially revascularized 9/34 (26.5) 148/628 (23.6) 1.17 (0.53-2.56) .70
Not revascularized 18/34 (52.9) 168/628 (26.8) 3.08 (1.54-6.18) .001
Stent 15/38 (39.5) 442/732 (60.4) 0.43 (0.22-0.83) .011
Drug-eluting stents 11/15 (73.3) 302/442 (68.3) 1.26 (0.39-4.02) .70
Surgical revascularization 0 44/1091 (4)
CABG indicates coronary artery bypass graft; CI, confidence interval; OR, odds ratio; PCI, percutaneous coronary intervention.
Data are expressed as n (%).
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CI, 0.27-2.36), and invasive strategy (HR=0.84; 95% 
CI, 0.37-1.91) (overall c2, 14.9). 
In the previous CABG group, an invasive strategy 




We found a lower prevalence of previous CABG 
in our population (5.6%) of unselected ACS patients, 
in contrast with rates of 20% previously reported in 
observational studies,6,7 but similar to the data most 
recently published by the Valiant trial (7%).17 In 
addition, it is worth noting that the prevalence of 
previous percutaneous revascularization was higher 
(9.6%, data not shown) for the overall population, 
probably reflecting an overall change in the treatment 
of coronary artery disease
As in other published series, our patients with 
a history of CABG were older, more often male, 
and more likely to have diabetes and a history of 
Follow-up
In-hospital mortality was similar in both groups 
(9.6% vs 5.9% P=.20). Loss to follow-up was 
6.3%; hence, data on the primary endpoint (all-
cause mortality at 1 year) were available for 1140 
patients.
No differences in 30-day, 6-month, or 1-year 
all-cause mortality were detected (Figure 1B). The 
incidence of 1-year MACE was also similar (22.0% 
vs 17.4%, P=.37) (Figure 1A); the result was also 
similar for readmissions for heart failure or MI (fatal 
or nonfatal) (Table 7). 
The 1-year readmission rate for UA was 
significantly higher for patients with a history of 
CABG (11.3% vs 3.1%, P=.001) (Figure 1C), and the 
results remained significant in the multivariate Cox 
regression analysis (hazard ratio [HR] =4.49; 95% 
confidence interval [CI], 1.7-12.1), in a model that 
included the following variables: previous CABG, 
diabetes (HR=1.76; 95% CI, 0.80-3.87), age over 75 
years (HR=0.98; 95% CI, 0.41-2.34), left ventricular 
ejection fraction lower than 40% (HR=0.80; 95% 
TABLE 6. Graft Lesions and Saphenous Graft PCI
Patients Venous Lesion Stent
 Stent   Direct   TIMI TIMI 
   Type Stenting 
Diameter Length
 Flow Before Flow After
1 99% stenosis occlusion Yes Cypher No 3 39 1 2
2 Two 75% proximal stenoses (intraluminal thrombus) Yes Taxus (2) Yes 4 (4) 12 (20) 1 3
3 99% proximal stenosis (intraluminal thrombus) Yes Cypher No 3 20 1 3
4 75% in-stent distal restenosis No (balloon)     1 2
5 99% medial stenosis Yes BMS Yes 4 23 1 3
6 75% proximal stenosis No (balloon)     2 3
7 99% proximal stenosis Yes BMS No 3 19 2 3
BMS indicates bare metal stent; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. 
Total number of venous bypass, 54; venous bypass with lesions, 24; total occlusion, 54.2%; ostial lesions, 41.2%; proximal lesions, 37.5%; distal lesions, 12.5%; total 
number of arterial bypass, 30; arterial bypass with lesions, 6; total occlusion, 3.0%.
TABLE 7. Outcomes in the Hospital and 1 Year After Discharge
 A (Previous CABG) B (No Previous CABG) OR (95% CI) P
Hospital stay, d 5 (4-6.5) 5 (4-6)  .27
In-hospital mortality 7/73 (9.6) 72/1223 (5.9) 1.70 (0.75-3.83) .20
Overall 30-day mortality 1/61 (1.6) 26/1079 (2.4) 0.68 (0.09-5.06) .70
Overall 6-month mortality 4/61 (6.6) 73/1079 (6.8) 0.98 (0.34-2.74) .95
Overall 1-year mortality 6/61 (9.8) 98/1079 (9.1) 1.09 (0.46-2.60) .84
MACE at 1 year 13/59 (22.0) 187/1076 (17.4) 1.34 (0.71-2.54) .37
Unstable angina at 1 year 7/62 (11.3) 34/1093 (3.1) 3.96 (1.68-9.34) .001
Reinfarction at 1 year 4/59 (6.8) 75/1079 (7.0) 0.97 (0.34-2.76) .96
PCI at 1 year 5/60 (8.3) 63/1088 (5.8) 1.48 (0.57-3.83) .41
Heart failure at 1 year 6/62 (9.7) 64/1108 (5.8) 1.75 (0.73-4.21) .21
Stroke at 1 year 1/62 (2.5) 28/1106 (2.5) 0.63 (0.08-4.72) .65
CABG indicates coronary artery bypass graft; CI, confidence interval; MACE, major adverse cardiac events; OR, odds ratio; PCI, percutaneous coronary intervention.
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conferred by the bypass vessels to the main coronary 
arteries and the more common occlusion of secondary 
branches as the cause of the ACS, as reported by 
Crean et al19 in 1985, could explain this finding.
Prognosis
In our population, although a history of CABG 
was associated in absolute terms with a poorer 
outcome in terms of in-hospital and 1-year 
mortality, the results were not statistically different. 
A higher number of patients and a longer follow-up 
could probably have enhanced the difference and, 
therefore, allowed us to conclude (as other authors 
have10,17,20-22) that patients with a history of CABG 
PCI and MI. This could be explained by adherence 
to guidelines in our series regarding surgical 
revascularization, and by the fact that this patient 
subgroup has a longer history of atherosclerotic 
disease.
The time between CABG and the ACS was similar 
to that previously reported in the literature,18 and 
varied between a median of 4 to 12.5 years. 
Patients with a history of CABG were admitted 
more often for a non-ST-elevation ACS and also 
had lower peak values of cardiac biomarkers for 
necrosis. This has also been previously reported and 
is probably related to the importance of the dual 
circulation (a protection mechanism for patients 
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revascularization leads to further revascularization 
(although angiographic data on the coronary lesions 
were not reported).
Moreover, data on percutaneous revascularization 
of saphenous venous grafts are still debated. The 
literature reports on randomized studies comparing 
stents versus balloon angioplasty for saphenous 
vein stenosis, which showed no statistical difference 
in restenosis during a 6-month period, but with an 
improved clinical outcome for elective stenting.25 
A recent Spanish study on 237 saphenous graft 
stenoses treated by DES or bare-metal stent (BMS) 
concluded a similar 30-month prognosis for both 
groups.26 Another study analyzed outcomes after 
PCI for patients with a history of CABG versus no 
history of CABG found that post-CABG patients 
had higher levels of event at 6 months, including 
death and MI, an outcome that was poorer for 
percutaneous transluminal coronary angioplasty 
(PTCA) in grafts versus native lesions. This poorer 
outcome could not be explained only by the 
patients’ baseline characteristics, but also because 
graft PCI was difficult and the lesions were complex 
and contained more luminal thrombi.27 In a recent 
retrospective study by Lei Ge et al,28 the benefits 
of PCI with a DES vs. BMS were established for 
venous graft stenoses (6-month MACE-free survival 
of 88.5% for DES vs 71.9% for BMS), and the use 
of BMS was an independent predictor of MACE. In 
this study, the authors reported a low rate of total 
occlusions, only 4.3% for DES and 3.3% for BMS, 
and distal protection devices were used in a third of 
patients. In contrast, data from a randomized trial 
(with angiographic control) that compared sirolimus 
DES with BMS for similar lesions found significant 
benefit for DES regarding in-stent loss and target 
vessel revascularization, but with no major difference 
for the clinical endpoints.29 In this trial, patients with 
left ventricular dysfunction, renal impairment, and 
totally occluded graft lesions were excluded. Despite 
these benefits, a recent retrospective study for DES 
in saphenous grafts used in actual clinical practice 
reported a high rate of adverse events at 1 year, 
and the authors identified 2 independent predictors 
of adverse events (death and infarction at 1 year): 
luminal thrombus and the length of the stented 
segment.30 A meta-analysis comparing DES vs BMS 
for saphenous grafts showed a lower incidence of 
major adverse cardiac events in the DES group over 
a 6- to 12-month period, mainly due to a reduction 
in target vessel revascularization.31 Nevertheless, 
there is a paucity of data on PCI in grafts, whether in 
a stable or unstable condition, and few randomized 
trials of insufficient power and short-term follow-
up.
In our previous subgroup of patients with ACS 
and a history of CABG, we chose full adherence to 
have a poorer outcome when they have an ACS 
(although a history of CABG was not an independent 
predictor of outcome, as assessed by the GRACE 
and the Valiant cohort studies). Nevertheless, we 
considered the following hypothesis to explain this 
more favorable outcome among our population 
with ACS and a history of CABG, when compared 
to previous data in the literature:
– The high prevalence of previous treatment with 
aspirin (78.9%), statins, beta blockers, and ACE 
inhibitors (50% in all 3 cases) before the current 
ACS. This rate was higher than the one published 
by the TIMI group,10 in which only 60% of patients 
were receiving aspirin and only 20% of patients were 
on ACE inhibitors, but comparable to a subanalysis 
of the GRACE registry.23 This finding reinforces 
the importance of the long-term protective effect 
achieved with these 4 drug classes.
– Adherence to medical treatment guidelines were 
quite high in our patient subgroup, both in-hospital 
and at discharge, with higher levels compared to the 
European Heart Surveys in 2004.24
– Another important aspect of our analysis was 
aggressive antiplatelet therapy (53.4%), especially 
with GP IIb/IIIa inhibitors. Only 19% of the Valiant 
trial population with a history of CABG were 
offered GP IIb/IIIa.17 We believe these drugs are a 
crucial treatment for dealing with unstable coronary 
lesions, regardless of the culprit lesion, as previously 
reported by the subgroup analysis of the PRISM-
PLUS and PURSUIT trial.21
– Similar rate of primary PCI between groups. In 
the Valiant trial, only 14% of patients with a history 
of CABG underwent PCI.
Revascularization
Almost 50% of patients with a history of CABG 
received an invasive strategy in the hospital, and most 
interventions were performed in native vessels with 
DES. In particular, there were multiple anatomic 
possibilities for the culprit lesion in these patients, 
and the ECG may not be that helpful in defining the 
location of the ischemia. Therefore, the decisions 
regarding revascularization in CABG were difficult, 
as the harm from a percutaneous intervention 
(especially because we were dealing with a complex 
lesion) could upset the delicate balance of native 
versus graft circulation. According to the data from 
a GRACE substudy, published by Gurfinkel et al,23 
on the benefits of a conservative versus invasive 
strategy for the patient subgroup with a history of 
CABG, there was no benefit based on the 6-month 
adjusted data, and a greater proportion of patients 
in the invasive group required unscheduled and 
therapeutic invasive procedures, which meant that 
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2005;352:875-83.
16. Ling LH, Enríquez-Sarano M, Seward JB, Orszulak TA, 
Schaff HV, Bailey KR, et al. Early surgery in patients with 
mitral regurgitation due to flail leaflets: a long-term outcome 
study. Circulation. 1997;96:1819-25.
17. Pai RG, Bansal RC, Shah PM. Doppler-derived rate of left 
ventricular pressure rise: its correlation with postoperative 
left ventricular function in mitral regurgitation. Circulation. 
1990;82:514-20.
18. Zile MR, Gaasch WH, Carroll JD, Levine HJ. Chronic 
mitral regurgitation: predictive value of pre-operative 
echocardiographic indexes of left ventricular function and wall 
stress. J Am Coll Cardiol. 1984;3:235-42.
19. Lee R, Haluska B, Leung DY, Case C, Mundy J, Marwick 
TH. Functional and prognostic implications of left ventricular 
contractile reserve in patients with asymptomatic severe mitral 
regurgitation. Heart. 2005;91:1383-4.
20. Leung DY, Griffin BP, Stewart WJ, Cosgrove DM 3rd, 
Thomas JD, Marwick TH. Left ventricular function after 
valve repair for chronic mitral regurgitation: predictive value 
medical treatment guidelines, as well as percutaneous 
revascularization whenever technically feasible, 
preferably in native vessels with a DES, based on 
previously reported data. Our venous grafts presented 
a very high proportion of total occlusion (“real 
world”) that limited PCI. In addition, no patients 
underwent a second surgical revascularization. 
Finally, a history of CABG was an independent 
predictor for a future readmission for unstable 
angina. This fact could have been related to more 
severe ischemia that probably was not amenable 
to revascularization, but curiously was not 
synonymous with a poorer medium-term prognosis. 
We believe, therefore, that this cohort of ACS 
patients represented a good example of the long-
term benefit of ischemic preconditioning and the 
collateral circulation which is the natural course of 
long-term atherosclerotic disease process.
Limitations
Our study included a small number of patients with 
ACS and a history of CABG ACS. We compared 2 
groups that had important baseline differences, and 
the statistical results could be misleading because 
the study was underpowered (power of 35.5% for in-
hospital mortality, 3.6% for 1-year mortality, 12.3% 
for 1-year MACE, and 50% for readmission due 
to UA). However, we had no data on medication 
during follow-up, and the observational period was 
limited to 12 months. Lastly, 6.3% of patients were 
lost to follow-up.
CONCLUSIONS
In our study population, a history of CABG was 
an independent predictor of hospital readmission 
for UA 1 year after the ACS, although it did not 
significantly influence survival or other ischemic 
endpoints in the short or medium term. These data 
stress the need for aggressive medical treatment in 
this high-risk ACS population.
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